SASS runs a concentrated portfolio of deeply undervalued stocks selected through M.D. Sass's institutional value framework. The fund targets companies trading at significant discounts to intrinsic value, typically holding 20-30 positions with meaningful conviction weights.
How It Works
The strategy employs classic value metrics like low price-to-book, price-to-earnings, and enterprise value ratios, but goes beyond simple screens. M.D. Sass applies qualitative overlays examining management quality, capital allocation, and catalysts for value realization. The concentrated approach allows for deeper research per position, with individual holdings potentially reaching 5-7% weights versus the 1-2% typical in diversified value funds.
Key Features
- True active management in ETF wrapper with institutional-grade value research process
- Concentrated portfolio enables meaningful position sizes when conviction is high
- Zero expense ratio makes this cheaper than virtually any active value fund
Risks
- Concentrated portfolios can underperform by 10-20% annually when value stocks stay cheap
- Limited track record since March 2026 launch means no proven performance through cycles
- Value traps could comprise 20-30% of holdings if catalyst analysis proves wrong
Who Should Own This
Best suited for patient investors who believe in mean reversion and want genuine active management without the typical 1-2% fee drag. Works as a satellite holding (5-10% of equity allocation) for those seeking to tilt toward deep value without abandoning core index exposure. The zero expense ratio makes this particularly attractive for long-term holders willing to endure potential multi-year stretches of underperformance.